{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Grillo P"],"funding":["The Marlene and Paolo Fresco Institute Post-doctoral Clinical Fellowship","NEXTGENERATIONEU (NGEU)","Michael J Fox Foundation, Parkinson's Foundation, Department of Defense","NINDS NIH HHS","National Recovery and Resilience Plan (NRRP)","National Institutes of Health","Ministry of University and Research (MUR)","NextGenerationEU","Ministero dell&apos;Università e della Ricerca","NIH HHS"],"pagination":["305-314"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904876"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(2)"],"pubmed_abstract":["<h4>Background</h4>α-Synuclein seed amplification assay on cerebrospinal fluid (CSF-αSyn-SAA) has shown high accuracy for Parkinson's disease (PD) diagnosis. The analysis of CSF-αSyn-SAA parameters may provide useful insight to dissect the heterogeneity of synucleinopathies.<h4>Objective</h4>To assess differences in CSF-αSyn-SAA amplification parameters in participants with PD stratified by rapid eye movement (REM) sleep behavior disorder (RBD), dysautonomia, GBA, and LRRK2 variants.<h4>Methods</h4>Clinical and CSF-αSyn-SAA data from the Parkinson's Progression Marker Initiative dataset were used. CSF-αSyn-SAA parameters included maximum fluorescence (F<sub>max</sub>), time to reach 50% of F<sub>max</sub> (T50), time to threshold (TTT), slope, and area under the curve (AUC). Sporadic PD (n"],"journal":["Movement disorders : official journal of the Movement Disorder Society"],"pubmed_title":["Association between the Amplification Parameters of the α-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease."],"pmcid":["PMC11904876"],"funding_grant_id":["U01 NS113851","MNESYS (PE0000006)","R56 NS131658","R01 NS131658","RF1 NS126406","PD210038","U01 NS122419","R01 NS133742","R01 NS116006"],"pubmed_authors":["Kang UJ","Concha-Marambio L","Riboldi GM","Pisani A","Grillo P"],"additional_accession":[]},"is_claimable":false,"name":"Association between the Amplification Parameters of the α-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.","description":"<h4>Background</h4>α-Synuclein seed amplification assay on cerebrospinal fluid (CSF-αSyn-SAA) has shown high accuracy for Parkinson's disease (PD) diagnosis. The analysis of CSF-αSyn-SAA parameters may provide useful insight to dissect the heterogeneity of synucleinopathies.<h4>Objective</h4>To assess differences in CSF-αSyn-SAA amplification parameters in participants with PD stratified by rapid eye movement (REM) sleep behavior disorder (RBD), dysautonomia, GBA, and LRRK2 variants.<h4>Methods</h4>Clinical and CSF-αSyn-SAA data from the Parkinson's Progression Marker Initiative dataset were used. CSF-αSyn-SAA parameters included maximum fluorescence (F<sub>max</sub>), time to reach 50% of F<sub>max</sub> (T50), time to threshold (TTT), slope, and area under the curve (AUC). Sporadic PD (n","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-12T10:19:18.189Z","creation":"2026-06-12T03:11:49.649Z"},"accession":"S-EPMC11904876","cross_references":{"pubmed":["39692283"],"doi":["10.1002/mds.30085"]}}